IRulya Therapeutics Inc. Common Stock
IRLA
126 hedge funds and large institutions have $1.76B invested in IRulya Therapeutics Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 44 increasing their positions, 28 reducing their positions, and 7 closing their positions.
386% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
79% more capital invested
Capital invested by funds: $983M → $1.76B (+$776M)
57% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 28
26% more funds holding
Funds holding: 100 → 126 (+26)
23% more call options, than puts
Call options by funds: $133M | Put options by funds: $108M
1.96% more ownership
Funds ownership: 62.69% → 64.65% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$19M |
| 2 |
ECG
EPIQ Capital Group
San Francisco,
California
|
+$14.9M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$12.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.68M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SUT
SC US (TTGP)
Menlo Park,
California
|
-$29.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.69M |
| 3 |
JG
Jefferies Group
New York
|
-$2.77M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$2.66M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$1.32M |
IRLA Hedge Fund Activity: Q3 2021 in Review
126 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q3 2021, worth a combined $1.76B — up 79% from $983M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new IRLA positions and 7 closed out — a net gain of 27 holders — while 44 added to existing stakes and 28 trimmed.
The largest buyer was Capital International Investors, adding an estimated $19M. The largest seller was SC US (TTGP), exiting entirely with an estimated $29.7M sold.
- 126 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q3 2021, up from 100 in Q2 2021.
- Funds reported $1.76B of IRulya Therapeutics Inc. Common Stock stock for Q3 2021, up 79% quarter-over-quarter.
- 34 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q3 2021 and 7 closed out, a net change of +27 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q3 2021 was Capital International Investors, an estimated $19M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q3 2021 was SC US (TTGP), an estimated $29.7M sold.
Based on aggregated 13F filings for Q3 2021.